Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study Corrigendum in /10.3892/ol.2017.6689

Sepúlveda‑Sánchez,Juan  Manuel; Conde‑Moreno,Antonio; Barón,Manuel; Pardo,Javier; Reynés,Gaspar; Belenguer,Antonio

doi:10.3892/ol.2017.5988

Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study

Corrigendum in: /10.3892/ol.2017.6689

Authors:
- Juan Manuel Sepúlveda‑Sánchez
- Antonio Conde‑Moreno
- Manuel Barón
- Javier Pardo
- Gaspar Reynés
- Antonio Belenguer
View Affiliations

Affiliations: Neurooncology Unit, Hospital 12 de Octubre, 28041 Madrid, Spain, Department of Radiation Oncology, Hospital Provincial de Castellón, 12002 Castellón, Spain, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain, Hospital Universitario Rey Juan Carlos, 28933 Madrid, Spain, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain, Hospital General de Castellón, 12002 Castellón, Spain
Published online on: April 5, 2017 https://doi.org/10.3892/ol.2017.5988
Pages: 4093-4100
Copyright: © Sepúlveda‑Sánchez et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present observational, multicenter, retrospective study investigated the efficacy and tolerability of lacosamide in controlling secondary epileptic seizures in patients with brain tumors in Spain. Data from the medical records of patients ≥18 years of age with brain tumors, who had received at least one dose of lacosamide for seizure management between July 2013 and November 2013, were collected. The primary and secondary objectives of the present study were to assess the effectiveness and tolerability of lacosamide. Data from 39 patients (mean age, 54.1 years; 66.7% male) were collected, where the two main reasons for initiation of lacosamide treatment were the lack of efficacy of other antiepileptic drugs (in 76.9% of patients) and the presence of adverse events (12.8%) associated with other antiepileptic drugs. At the initiation of treatment, patients received a mean lacosamide dose of 138.5±68.3 mg/day. At 6 months, lacosamide had significantly reduced the mean number of seizures from 26.4 (standard deviation [SD], 50.4) seizures for the 6 months prior to lacosamide initiation to a mean of 9.4 (SD, 22.8) seizures during the 6 months subsequent to lacosamide initiation; P<0.001. Lacosamide was generally well tolerated; of the 25 patients who had complete safety data available at a 6‑month follow‑up, 3 patients (12%) reported an adverse event, including dizziness, asthenia, instability and irritability. The present retrospective analysis suggested that lacosamide is an effective and well‑tolerated treatment in patients experiencing seizures due to brain tumors. Additional prospective studies with a larger patient population and randomized trial design are warranted.

View Figures

View References

1	Hildebrand J, Lecaille C, Perennes J and Delattre JY: Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology. 65:212–215. 2005. View Article : Google Scholar : PubMed/NCBI
2	Rossetti AO and Stupp R: Epilepsy in brain tumor patients. Curr Opin Neurol. 23:603–609. 2010. View Article : Google Scholar : PubMed/NCBI
3	Singh G, Rees JH and Sander JW: Seizures and epilepsy in oncological practice: Causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatry. 78:342–349. 2007. View Article : Google Scholar : PubMed/NCBI
4	van Breemen MS, Wilms EB and Vecht CJ: Epilepsy in patients with brain tumours: Epidemiology, mechanisms, and management. Lancet Neurol. 6:421–430. 2007. View Article : Google Scholar : PubMed/NCBI
5	Rudà R and Soffietti R: What is new in the management of epilepsy in gliomas? Curr Treat Options Neurol. 17:3512015. View Article : Google Scholar : PubMed/NCBI
6	Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA and Wen PY: Medical management of brain tumors and the sequelae of treatment. Neuro Oncol. 17:488–504. 2015. View Article : Google Scholar : PubMed/NCBI
7	Smith KC: The management of seizures in brain tumor patients. J Neurosci Nurs. 42:28–39. 2010. View Article : Google Scholar : PubMed/NCBI
8	Haque N, Thrasher K, Knowles EE Jr, Werk HC Jr and Sholiton LJ: Studies on dexamethasone metabolism in man: Effect of diphenylhydantoin. J Clin Endocrinol Metab. 34:44–50. 1972. View Article : Google Scholar : PubMed/NCBI
9	Gambertoglio JG, Holford NH, Kapusnik JE, Nishikawa R, Saltiel M, Stanik-Lizak P, Birnbaum JL, Hau T and Amend WJ Jr: Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. Kidney Int. 25:119–123. 1984. View Article : Google Scholar : PubMed/NCBI
10	Chalk JB, Ridgeway K, Brophy T, Yelland JD and Eadie MJ: Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry. 47:1087–1090. 1984. View Article : Google Scholar : PubMed/NCBI
11	Warren RD and Bender RA: Drug interactions with antineoplastic agents. Cancer Treat Rep. 61:1231–1241. 1977.PubMed/NCBI
12	Rudà R, Bello L, Duffau H and Soffietti R: Seizures in low-grade gliomas: Natural history, pathogenesis, and outcome after treatments. Neuro Oncol. 14 Suppl 4:iv55–iv64. 2012. View Article : Google Scholar : PubMed/NCBI
13	Fincham RW and Schottelius DD: Decreased phenytoin levels in antineoplastic therapy. Ther Drug Monit. 1:277–283. 1979. View Article : Google Scholar : PubMed/NCBI
14	Perucca E and Pisani F: Pharmacokinetics and interactions of the new antiepileptic drugs. Epilepsy Res Suppl. 3:79–88. 1991.PubMed/NCBI
15	Beydoun A, D'Souza J, Hebert D and Doty P: Lacosamide: Pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother. 9:33–42. 2009. View Article : Google Scholar : PubMed/NCBI
16	Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P and Rudd GD: Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 48:1308–1317. 2007. View Article : Google Scholar : PubMed/NCBI
17	Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD and Doty P; SP754 Study Group, : Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia. 51:958–967. 2010. View Article : Google Scholar : PubMed/NCBI
18	Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D and Sullivan T; SP755 Study Group, : Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia. 50:443–453. 2009. View Article : Google Scholar : PubMed/NCBI
19	Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, et al: Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: Clinical article. J Neurosurg. 118:1183–1187. 2013. View Article : Google Scholar : PubMed/NCBI
20	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
21	Pellerino A, Magistrello M, Franchino F, Nicolotto E, Soffietti R and Rudà R: Efficacy and tolerability of lacosamide in patients with glioma: A prospective study. Eur J Neurol. 22 Suppl 1:732015.
22	European Medicines Agency, . Lacosamide (Vimpat 50 mg tablets): Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000863/WC500050338.pdf[Accessed 2016 May 20].
23	US Food and Drug Administration, . Vimpat (lacosamide) tablets and injection: US prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf2016 May 20;
24	Klein M, Engelberts NH, van der Ploeg HM, Kasteleijn-Nolst Trenité DG, Aaronson NK, Taphoorn MJ, Baaijen H, Vandertop WP, Muller M, Postma TJ and Heimans JJ: Epilepsy in low-grade gliomas: The impact on cognitive function and quality of life. Ann Neurol. 54:514–520. 2003. View Article : Google Scholar : PubMed/NCBI
25	Maschio M, Dinapoli L, Mingoia M, Sperati F, Pace A, Pompili A, Carapella CM, Vidiri A and Muti P: Lacosamide as add-on in brain tumor-related epilepsy: Preliminary report on efficacy and tolerability. J Neurol. 258:2100–2104. 2011. View Article : Google Scholar : PubMed/NCBI
26	Yap KY, Chui WK and Chan A: Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther. 30:1385–1407. 2008. View Article : Google Scholar : PubMed/NCBI
27	Landmark C Johannessen and Patsalos PN: Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 10:119–140. 2010. View Article : Google Scholar : PubMed/NCBI